NCT06864182View on ClinicalTrials.gov

Relative Bioavailability Study of CX2101A for the Treatment of COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

May 25, 2024

Study Completion Date

May 25, 2024

Conditions
COVID-19Coronavirus Infection
Interventions
DRUG

CX2101A tablet

CX2101A tablet

DRUG

CX2101A placebo tablet

CX2101A placebo tablet

DRUG

CX2101A enteric-coated tablet

CX2101A enteric-coated tablet

DRUG

CX2101A placebo enteric-coated tablet

CX2101A placebo enteric-coated tablet

Trial Locations (1)

311202

Zhejiang Xiaoshan Hospital, Hangzhou

Sponsors
All Listed Sponsors
lead

Heronova Pharmaceuticals

INDUSTRY

NCT06864182 - Relative Bioavailability Study of CX2101A for the Treatment of COVID-19 | Biotech Hunter | Biotech Hunter